Skip to main content
Contact Us
Subscribe
E-Edition
56°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AN2 Therapeutics, Inc. - Common Stock
(NQ:
ANTX
)
1.040
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AN2 Therapeutics, Inc. - Common Stock
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
August 16, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
August 13, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
August 08, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 13, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Jefferies Healthcare Conference
May 25, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
May 01, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 29, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
January 31, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 09, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 19, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 06, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022
NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
May 09, 2022
From
AN2 Therapeutics, Inc.
Via
Business Wire
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
May 20, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.